TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33576412

Group type: EXPERIMENTAL
Intervention: Dynamic retinal vessel analysis (DVA) using untargeted machine learning for predicting CV mortality.
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Dynamic retinal vessel analysis (DVA) for predicting all-cause mortality.
Number of subjects: 214
Study: 33576546

Group type: EXPERIMENTAL
Intervention: Episodic treatment
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 94
Study: 33577377

Group type: EXPERIMENTAL
Intervention: simplified geriatric assessment (sGA)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: Elderly Prognostic Index (EPI)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: original geriatric assessment (oGA)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: overall survival (OS)
Number of subjects: 1163
Study: 33577756

Group type: EXPERIMENTAL
Intervention: Micropulse trans-scleral laser therapy (mTLT)
Number of subjects: 52
Study: 33577985

Group type: COMPARATOR
Intervention: Liquid chromatography-mass spectrometry (LC-MS) metabolomics analyses
Number of subjects: 100
Study: 33578396

Group type: EXPERIMENTAL
Intervention: MCC-IMS for SARS-CoV-2 detection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MCC-IMS for influenza-A detection
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (44 patients)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MCC-IMS
Number of subjects: 75
Study: 33578615

Group type: EXPERIMENTAL
Intervention: Navigated transcranial magnetic stimulation (TMS) priming with transcranial direct current stimulation (tDCS) combined with constraint-induced movement therapy (CIMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS combined with constraint-induced movement therapy (CIMT)
Number of subjects: 0
Study: 33579196

Group type: EXPERIMENTAL
Intervention: Colonoscopy surveillance
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical testing (FIT)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Platinum levels in blood and urine
Number of subjects: 234
Study: 33579197

Group type: EXPERIMENTAL
Intervention: CT/TT genotype (minor T allele of rs3918242)
Number of subjects: 498

Group type: COMPARATOR
Intervention: rs3918242
Number of subjects: 498
Study: 33579213

Group type: EXPERIMENTAL
Intervention: Wireless physiologic monitoring system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard of care (manual vital sign measurement when clinically indicated)
Number of subjects: 0
Study: 33579242

Group type: EXPERIMENTAL
Intervention: Mobile technology-based intervention informed by behavioral economics
Number of subjects: 41
Study: 33579332

Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy (ABFT) for 16 weeks, consisting of weekly therapy sessions (family/individual or both) according to the treatment manual.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) for 16 weeks, not monitored.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ABFT and TAU both assessed using the Beck Depression Inventory-II (BDI-II) for self-reported depressive symptoms at multiple time points (baseline, and after 4, 6, 8, 10, 12, 14, and 16 weeks).
Number of subjects: 60
Study: 33579338

Group type: EXPERIMENTAL
Intervention: Three-dimensional preoperative planning
Number of subjects: 63
Study: 33579396

Group type: EXPERIMENTAL
Intervention: CVD preventive care in HIV specialty clinics
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: HIV care providers' roles in CVD prevention
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Multi-level interventions for HIV providers
Number of subjects: 37
Study: 33579579

Group type: EXPERIMENTAL
Intervention: No symptoms reported
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Flu-like symptoms cluster
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Combined generic and flu-like symptoms cluster
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Taste/smell disorders
Number of subjects: 6680
Study: 33579739

Group type: EXPERIMENTAL
Intervention: Atezolizumab and nab-paclitaxel (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo comparator arm of the IMpassion130 trial
Number of subjects: 0
Study: 33579774

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (HFOT)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) alternating with HFOT
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: NIV alternating with standard oxygen
Number of subjects: 330
Study: 33579966

Group type: EXPERIMENTAL
Intervention: Communication intervention engaging family care partners
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intervention patients whose care partners logged into MyChart
Number of subjects: 118
Study: 33580032

Group type: EXPERIMENTAL
Intervention: Active iTBS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 22
Study: 33580261

Group type: EXPERIMENTAL
Intervention: High amounts of SARS-CoV-2 virus (indicated by PCR Ct value)
Number of subjects: 9449

Group type: EXPERIMENTAL
Intervention: Low amounts of SARS-CoV-2 virus
Number of subjects: 9449

Group type: EXPERIMENTAL
Intervention: Serology-positive subjects
Number of subjects: 9449
Study: 33580363

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 12
Study: 33580495

Group type: EXPERIMENTAL
Intervention: Trabectome ab interno trabeculotomy combined with cataract extraction (phaco-AIT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C combined with cataract extraction (phaco-Trab)
Number of subjects: 19
Study: 33580657

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms at admission
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Increase in insomnia symptoms from admission to 3 months
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms at 3 months
Number of subjects: 154
Study: 33580776

Group type: EXPERIMENTAL
Intervention: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for PCS
Number of subjects: 665
Study: 33580779

Group type: COMPARATOR
Intervention: High-sensitivity troponin T (hs-cTnT) reference
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Panel of microRNAs (miR-122, miR-133, and miR-134)
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Combination of miRNA panel and hs-cTnT reference
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: miRNAs
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Single miRNAs
Number of subjects: 1042
Study: 33580980

Group type: EXPERIMENTAL
Intervention: Decitabine and venetoclax
Number of subjects: 0
Study: 33581080

Group type: EXPERIMENTAL
Intervention: Tezacaftor-ivacaftor (oral tezacaftor 100 mg once daily and oral ivacaftor 150 mg once every 12 hours for up to 96 weeks)
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Tezacaftor-ivacaftor
Number of subjects: 1042
Study: 33581302

Group type: EXPERIMENTAL
Intervention: Cutting-through group (46 patients)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No cutting-through group (32 patients)
Number of subjects: 78
Study: 33581379

Group type: EXPERIMENTAL
Intervention: Accelerated rTMS course (arTMS) of 6 sessions/day over 5 days (30 total) followed by tapering course of daily sessions (up to 25)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-frequency (LF) 1 Hz stimulation protocol (360 pulses per session)
Number of subjects: 48
Study: 33581722

Group type: EXPERIMENTAL
Intervention: Hearing Aids (HA)
Number of subjects: 100
Study: 33581739

Group type: EXPERIMENTAL
Intervention: Multimodal physical activity, nutrition, and palliative symptom management intervention
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Exercise classes
Number of subjects: 23
Study: 33581976

Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: T3-4 lesions
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Pelvic lymph node involvement
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Para-aortic lymph node involvement
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: T1-2 patients with no nodes, pelvic nodes alone or para-aortic nodes at diagnosis
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: T3-4 patients with no nodes, pelvic nodes alone or para-aortic nodes at diagnosis
Number of subjects: 402
Study: 33582086

Group type: EXPERIMENTAL
Intervention: Online assessment of regurgitation using videodensitometry
Number of subjects: 100

Group type: COMPARATOR
Intervention: Offline assessment by core laboratory
Number of subjects: 100
Study: 33582392

Group type: EXPERIMENTAL
Intervention: Trans-arterial chemoembolization
Number of subjects: 34000

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy
Number of subjects: 34000

Group type: EXPERIMENTAL
Intervention: Percutaneous tumour ablations
Number of subjects: 34000

Group type: EXPERIMENTAL
Intervention: Surgical tumour resections
Number of subjects: 34000

Group type: EXPERIMENTAL
Intervention: Minimally invasive procedures
Number of subjects: 34000

Group type: EXPERIMENTAL
Intervention: Percutaneous thermal ablation
Number of subjects: 34000
Study: 33582418

Group type: EXPERIMENTAL
Intervention: 30 mg of mirogabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg of pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33582955

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study: 33583058

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) plus social skills training
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo plus social skills training
Number of subjects: 67
Study: 33583206

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0
Study: 33583404

Group type: EXPERIMENTAL
Intervention: Activity/participation goals
Number of subjects: 2591

Group type: EXPERIMENTAL
Intervention: Non-classifiable goals
Number of subjects: 2591
Study: 33583408

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51
Study: 33583610

Group type: EXPERIMENTAL
Intervention: Transitions Clinic Network (TCN) intervention
Number of subjects: 800

Group type: COMPARATOR
Intervention: Referral to standard primary care
Number of subjects: 800
Study: 33583755

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) patients
Number of subjects: 6217

Group type: COMPARATOR
Intervention: Control group (non-AF patients)
Number of subjects: 6217
Study: 33584209

Group type: EXPERIMENTAL
Intervention: Spinal Epidural Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33584491

Group type: EXPERIMENTAL
Intervention: Paclitaxel Coated Balloon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare Metal Stent
Number of subjects: 0
Study: 33584535

Group type: EXPERIMENTAL
Intervention: MRI-derived biomarker cT1
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: MRI-derived biomarker PDFF
Number of subjects: 264
Study: 33585031

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg intravenously or 162 mg subcutaneously
Number of subjects: 93

Group type: COMPARATOR
Intervention: Corticosteroids (CS) methylprednisolone 80 mg/day
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study: 33585179

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia
Number of subjects: 3748

Group type: COMPARATOR
Intervention: Benign subjects with benign thyroid nodules
Number of subjects: 3748
Study: 33585394

Group type: EXPERIMENTAL
Intervention: Distance Learning Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 33585418

Group type: EXPERIMENTAL
Intervention: Interjoint coordination measures post-stroke
Number of subjects: 0
Study: 33585500

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 4000
Study: 33585503

Group type: EXPERIMENTAL
Intervention: Low Soluble Receptor for Advanced Glycation End Products
Number of subjects: 0
Study: 33585521

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33585533

Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33585799

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) transfusion; 1 unit (68.2% of patients), 2 units (27.3% of patients), 3 units (4.5% of patients)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) transfusion
Number of subjects: 22
Study: 33585999

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10-25 mg bid) in combination with weekly paclitaxel (80 mg/m)
Number of subjects: 19
Study: 33586138

Group type: COMPARATOR
Intervention: Aldosterone antagonists (spironolactone or eplerenone)
Number of subjects: 1446
Study: 33586174

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB-UVB) treatment for 36 sessions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB-UVB) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 20
Study: 33586581

Group type: EXPERIMENTAL
Intervention: Bendamustine 200 mg/m²
Number of subjects: 34
Study: 33586590

Group type: EXPERIMENTAL
Intervention: RO6870810 (BET inhibitor)
Number of subjects: 32
Study: 33586674

Group type: EXPERIMENTAL
Intervention: Sema3G supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endothelial-specific Sema3G knockout
Number of subjects: 0
Study: 33587156

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment for 2 min on Staphylococcus aureus in collagen-elastin matrices
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment for 2 min on Staphylococcus aureus on dermal samples
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment for 2 min on human dermal samples
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Repeated daily CAP treatments for 2 min on dermal samples
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Repeated CAP treatment for 2 min on ex vivo human burn wound models
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment for 3× 20" on intact skin of volunteers
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment on intact skin of 15 volunteers contaminated with Pseudomonas aeruginosa
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lowering the plasma power during CAP treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) treatment
Number of subjects: 25
Study: 33587350

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nilotinib + Simvastatin
Number of subjects: 0
Study: 33587435

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-based DAA therapy + Ribavirin (RBV)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sofosbuvir-based DAA therapy
Number of subjects: 29
Study: 33587499

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 181
Study: 33587504

Group type: EXPERIMENTAL
Intervention: High HCV knowledge
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Living with HCV for a decade
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Low HIV knowledge
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Low HCV knowledge
Number of subjects: 151
Study: 33587508

Group type: EXPERIMENTAL
Intervention: Maternal HIV
Number of subjects: 1450
Study: 33588101

Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) performed at inclusion
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) performed at 1-month follow-up
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) performed at 2-month follow-up
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) with liver stiffness less than 10 kPa
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) with liver stiffness greater than 25 kPa
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Transient elastography (TE) for patients with initial liver stiffness of 10 to 25 kPa
Number of subjects: 259
Study: 33588145

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 45
Study: 33588149

Group type: EXPERIMENTAL
Intervention: ABTL0812 at 1300 mg three times a day (RP2D)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ABTL0812 at 500 mg once a day to 2000 mg twice a day (escalation phase)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ABTL0812
Number of subjects: 29
Study: 33588912

Group type: EXPERIMENTAL
Intervention: Automated detection of reverse triggering using airway pressure (Paw) and flow waveforms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reverse triggering (RT)
Number of subjects: 20
Study: 33588922

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg intravenously once weekly for Cycles 1 and 2, every other week for Cycles 3 through 6, and every 4 weeks thereafter until progression or unacceptable toxicity; all cycles were 28 days.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg intravenously
Number of subjects: 32
Study: 33588925

Group type: EXPERIMENTAL
Intervention: cDPP3 levels upon admission and 24 hours later
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: cDPP3 levels upon admission
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: cDPP3 levels > 40.4 ng/mL upon admission
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Persistently elevated cDPP3 at 24 hours
Number of subjects: 585
Study: 33588932

Group type: EXPERIMENTAL
Intervention: Home delivered meal service
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 33588948

Group type: EXPERIMENTAL
Intervention: Resistance and high-intensity interval training (RT-HIIT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic and high-intensity interval training (AT-HIIT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 88
Study: 33589404

Group type: EXPERIMENTAL
Intervention: Triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Higher insulin concentration
Number of subjects: 454
Study: 33589447

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydroartesinin-piperaquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous deployment of three ACTs
Number of subjects: 0
Study: 33589520

Group type: EXPERIMENTAL
Intervention: αPD-1-mesoCAR-T cells
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: αPD-1-mesoCAR-T cells combined with apatinib
Number of subjects: 1
Study: 33589539

Group type: EXPERIMENTAL
Intervention: Normal weight (BMI 18.5-24.9 kg/m²)
Number of subjects: 25384

Group type: EXPERIMENTAL
Intervention: Overweight individuals
Number of subjects: 25384

Group type: EXPERIMENTAL
Intervention: Underweight individuals
Number of subjects: 25384
Study: 33589538

Group type: EXPERIMENTAL
Intervention: Intensive arm motor therapy
Number of subjects: 77
Study: 33589714

Group type: EXPERIMENTAL
Intervention: Multi-domain program (24-week, bi-weekly) including dual-task exercises, cognitive training, and mobile application-based nutritional guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-domain program
Number of subjects: 0
Study: 33590273

Group type: EXPERIMENTAL
Intervention: bolus injection of LAT-1 targeting PET tracer
Number of subjects: 6
Study: 33590300

Group type: EXPERIMENTAL
Intervention: Genome-wide average African ancestry proportions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genome-wide average European ancestry proportions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genome-wide average Amerindigenous ancestry proportions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genome-wide average East Asian ancestry proportions
Number of subjects: 0
Study: 33590349

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IA)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (EA)
Number of subjects: 108
Study: 33590355

Group type: EXPERIMENTAL
Intervention: Chronic high-intensity vagus nerve stimulation (≥ 2.0 mA)
Number of subjects: 21
Study: 33590674

Group type: EXPERIMENTAL
Intervention: Low glycemic diet intervention for 6 months
Number of subjects: 28
Study: 33590771

Group type: EXPERIMENTAL
Intervention: PCSK9, LDLR and MPO measurements
Number of subjects: 0
Study: 33590821

Group type: EXPERIMENTAL
Intervention: Withings Sleep Analyzers
Number of subjects: 118
Study: 33590989

Group type: EXPERIMENTAL
Intervention: New minimally invasive bronchoscopic approaches and techniques for lung cancer and chronic lung diseases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Navigation platforms for diagnosing and treating peripheral pulmonary nodules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound for diagnosis of mediastinal and hilar adenopathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryobiopsy for diagnosis of diffuse lung diseases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible and rigid bronchoscopy for managing benign and malignant central airway obstruction
Number of subjects: 0
Study: 33590994

Group type: EXPERIMENTAL
Intervention: Flywheel exercise at 0.075 kg·m2 moment of inertia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Flywheel exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Aerobic fitness
Number of subjects: 19

Group type: COMPARATOR
Intervention: Age
Number of subjects: 19

Group type: COMPARATOR
Intervention: Max oxygen uptake
Number of subjects: 19
Study: 33590998

Group type: EXPERIMENTAL
Intervention: Medical treatment alone
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Vasoactive Inotropic Score quartiles
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Vasoactive Inotropic Score as a continuous value
Number of subjects: 836